These findings suggest that while PROX1 may influence tumor biology, differentiation, or even tumor progression in cases of NSCLC, it is unlikely to serve as a standalone prognostic biomarker in those patients that have undergone surgical resection with curative intent. Here, PROX1 is linked to non-small cell lung carcinoma.